Xeris Pharmaceuticals

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Mar 14, 2025FDAGlucagon — GVOKE VIALDX

May 15, 2023TrialStudy of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Aug 22, 2019TrialPhase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Aug 22, 2019TrialGlucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Jul 24, 2019FDAGlucagon — BAQSIMI

May 10, 2019TrialGlucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

Sep 27, 2018TrialG-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

Mar 15, 2018TrialGlucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

4 more events

Jan 23, 2018TrialG-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Mar 27, 2017TrialGlucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

Mar 15, 2017TrialSafety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Oct 1, 2016TrialCSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Glucagon4 patentsFeb 16, 2036 GlucagonSep 23, 2039

Regulatory

Regulatory Timeline

19822 events

FDAJan 1

Glucagon — GLUCAGON

Application NDA012122 (NDA)

FDAJan 1

Daranide — DARANIDE

Application NDA011366 (NDA)

19982 events

FDASep 11

Glucagon — GLUCAGON

Application NDA020928 (NDA)

FDAJun 22

Glucagon — GLUCAGEN

Application NDA020918 (NDA)

20151 event

FDAMay 8

Glucagon — GLUCAGON

Application NDA201849 (NDA)

20191 event

FDAJul 24

Glucagon — BAQSIMI

Application NDA210134 (NDA)

20251 event

FDAMar 14

Glucagon — GVOKE VIALDX

Application NDA212097 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)